<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="926">
  <stage>Registered</stage>
  <submitdate>16/10/2005</submitdate>
  <approvaldate>16/10/2005</approvaldate>
  <nctid>NCT00240305</nctid>
  <trial_identification>
    <studytitle>A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Placebo Controlled, Crossover Dose-Ranging Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>4522AS/0004</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic Syndrome</healthcondition>
    <healthcondition>Dyslipidemia</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Rosuvastatin

Treatment: drugs: Rosuvastatin


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Determine the dose-related effect of treatment with rosuvastatin on production &amp; fractional catabolism of apolipoprotein A-I (apoA-I) and apolipoprotein A-II (apoA-II), &amp; on the plasma apoA-I, apoA-II &amp; high-density lipoprotein cholesterol (HDL-C) c</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Determine the dose-related effect of treatment with rosuvastatin on cellular cholesterol efflux,total cholesterol, low-density lipoprotein cholesterol (LDL-C), non-LDL-C, triglyceride &amp; pre1-HDL concentrations,HDL2,HDL3 cholesterol ratio</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cholesteryl ester transfer protein (CETP) and lecithin:cholesterol acyl transferase (LCAT) activity</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lathosterol and campesterol, total apolipoprotein B (apoB), nonesterified fatty acids (NEFA) and apolipoprotein C-III (apoC-III) plasma concentrations.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Signed informed consent

          -  male aged 30 to 70 years of age

          -  LDL-C &lt;6 mmol/L

          -  HDL-C =1.2 mmol/L

          -  at least 2 of the following:

          -  insulin resistance (fasting glucose &gt;6 mmol/L or insulin &gt;10 mU/L or HOMA score &gt;2.5)

          -  central obesity (waist circumference &gt;=94 cm).

          -  plasma triglycerides &gt;=1.7 and &lt;4.5 mmol/L.

          -  blood pressure &gt;=130/ &gt;=85 mm Hg or on drug treatment for hypertension</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  LDL cholesterol &gt;=6 mmol/L

          -  pre-existing or history of cardiovascular disease, diabetes, renal dysfunction,
             anaemia, history of significant dyspepsia or gastrointestinal disease

          -  apolipoprotein genotype E2/E2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Research Site - Perth</hospital>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to investigate the dose-related effect of treatment with
      rosuvastatin on production and fractional catabolism of apolipoprotein A-I (apoA-I) and
      apolipoprotein A-II (apoA-II), and on the plasma apoA-I, apoA-II and high-density lipoprotein
      cholesterol (HDL-C) concentration.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00240305</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerald F. Watts, BSc PhD MD</name>
      <address>University Department of Medicine, Royal Perth Hospital, University of Western Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>